Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Leucovorin Calcium for Injection, USP, in 50 mg per vial in a single-dose vial, 100 mg per vial in a single-dose vial, 200 mg per vial in a single-dose vial, 350 mg per vial in a single-dose vial, and 500 mg per vial in a single-dose vial.
Meitheal will offer Leucovorin Calcium for Injection, USP in a pack of 1 vial for all 5 presentations.
“We are pleased to bring Leucovorin to the United States Market during a time of product shortage”, said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. “At Meitheal, we understand how important it is to have a reliable supply. Launching Leucovorin is just one more example of our ability to follow through on our commitment to our customers and their patients' needs.”
As of September 5, 2023 both the FDA and the ASHP websites list Leucovorin on drug shortages.
ABOUT LEUCOVORIN CALCIUM FOR INJECTION, USP
- Leucovorin Calcium for Injection rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists.
- Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible.
- Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.
For full prescribing and safety information, please click on the following link.
Learn more about Leucovorin Calcium for Injection, USP
